----
Current ValuationThe current P/E ratio is -0.42, within the reasonable range, cheaper than 68.4% of the time in the past 5 years, and the industry ranks 34/70, the industry Median -0.14.
-0.417xP/E
$0.82Stock price
$-1.97Earnings per share
-0.417xP/E
Stock price$0.82Earnings per share$-1.97
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 5.22x
- Typical range
- -4.14x–9.81x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
010203040
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
LYVUSLive Nation | -163.35x | 107.03% | $42.15B |
LLYVKUSLiberty Live Holdings - C | -22.12x | -- | $9.73B |
LLYVAUSLiberty Live | -21.38x | -- | $9.41B |
SPHRUSSphere ENT | -49.10x | 458.92% | $3.77B |
MANUUSManchester United | -64.75x | 31.83% | $3.71B |
LIONUSLionsgate Studios | -31.18x | 82.70% | $3.70B |
BATRAUSAtlanta Braves | -56.39x | -- | $3.62B |
BATRKUSAtlanta Braves Holdings - C | -51.71x | -- | $3.32B |
AMCUSAMC ENT | -5.28x | 93.58% | $2.93B |
STUBUSStubhub - CL | -1.25x | 105.18% | $2.32B |
IQUSiQIYI | -7.05x | 312.85% | $849.13M |
ANGXUSAngel Studios | -4.18x | 66.12% | $648.04M |
STRZUSStarz ENT | -1.35x | -- | $400.02M |
PODCUSPodcastOne | -19.22x | 20.00% | $60.51M |
CASTUSFreecast | -2.66x | 62.90% | $65.01M |
LVOUSLiveOne | -1.61x | 39.92% | $33.73M |
CNVSUSCineverse | -3.24x | 19.39% | $36.61M |
RDIUSReading | -2.98x | 69.11% | $37.54M |
RDIBUSReading | -19.08x | -- | $240.35M |
GAIAUSGaia | -4.19x | 129.17% | $32.80M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
